Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022
September 12, 2022 07:00 ET
|
Plus Therapeutics Inc.
Phase 1 data indicates that direct administration of 186RNL targeted radiotherapeutic is safe in patients with recurrent glioblastoma Statistically significant overall survival benefit observed with...
Plus Therapeutics to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
September 08, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Announces FDA Meeting Summary for Lead Drug Candidate
September 06, 2022 07:00 ET
|
Plus Therapeutics Inc.
NIH-funded ReSPECT-GBM Phase 2 trial to start in 2022 ReSPECT-GBM Phase 2 to focus on 186RNL dose expansion, safety and efficacy data to support future registrational trial AUSTIN, Texas, Sept. 06,...
Plus Therapeutics Announces Summary of FDA Meeting on Company’s cGMP Manufacturing Process for Lead Drug Candidate
August 29, 2022 07:00 ET
|
Plus Therapeutics Inc.
cGMP production of 186RNL targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future ReSPECT™ clinical trials AUSTIN, Texas, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Plus...
Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022
August 23, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics Awarded $17.6 Million from State of Texas
August 17, 2022 17:46 ET
|
Plus Therapeutics Inc.
Funding from the Cancer Prevention and Research Institute of Texas (CPRIT), the second largest global public funder of cancer research, will support the majority of the development costs of 186RNL for...
Plus Therapeutics Announces Share Repurchase Program
August 15, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and...
Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
August 13, 2022 13:06 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, Aug. 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
July 28, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...
Plus Therapeutics to Present at Inaugural Targeted Radiopharmaceuticals Summit
July 27, 2022 07:00 ET
|
Plus Therapeutics Inc.
AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for...